litlas
Log inCreate account

Brian Gazzard

Active 1978–2023

113
Papers
22,768
Citations
91
h-index
113
i10-index

Citations

Citations per year for Brian Gazzard1980: 2 citations1982: 1 citations1983: 1 citations1984: 8 citations1985: 21 citations1986: 7 citations1987: 5 citations1988: 1 citations1989: 9 citations1990: 6 citations1991: 14 citations1992: 13 citations1993: 9 citations1994: 19 citations1995: 18 citations1996: 27 citations1997: 31 citations1998: 73 citations1999: 84 citations2000: 115 citations2001: 127 citations2002: 149 citations2003: 167 citations2004: 227 citations2005: 182 citations2006: 219 citations2007: 236 citations2008: 333 citations2009: 243 citations2010: 190 citations2011: 178 citations2012: 167 citations2013: 162 citations2014: 113 citations2015: 78 citations2016: 152 citations2017: 107 citations2018: 85 citations2019: 350 citations2020: 265 citations2021: 222 citations2022: 142 citations2023: 90 citations2024: 135 citations2025: 41 citations2026: 2 citations1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,218 citing papers, 31.4% of this breakdownUnited Kingdom: 742 citing papers, 10.5% of this breakdownFrance: 385 citing papers, 5.5% of this breakdownCanada: 286 citing papers, 4.1% of this breakdownGermany: 282 citing papers, 4% of this breakdownItaly: 269 citing papers, 3.8% of this breakdownAustralia: 239 citing papers, 3.4% of this breakdownNetherlands: 214 citing papers, 3% of this breakdownSpain: 213 citing papers, 3% of this breakdownSwitzerland: 205 citing papers, 2.9% of this breakdownSouth Africa: 202 citing papers, 2.9% of this breakdownChina: 135 citing papers, 1.9% of this breakdown
0%31.4%Other 23.6%

Institutions

Fields

  • Medicine70.7%
  • Immunology and Microbiology21.8%
  • Biochemistry, Genetics and Molecular Biology3.3%
  • Health Professions0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Neuroscience0.4%
  • Other2.5%

Topics

  • HIV/AIDS Research and Interventions12.5%
  • HIV Research and Treatment11.9%
  • HIV/AIDS drug development and treatment10.5%
  • HIV-related health complications and treatments6.3%
  • Viral-associated cancers and disorders3.4%
  • Immune Cell Function and Interaction3.1%
  • Other52.3%

Coauthors

All papers

Open in search
  1. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

    Authors: Sheena McCormack, David Dunn, Monica Desai, David Dolling, Mitzy Gafos, Richard Gilson, Ann Sullivan, Amanda Clarke, Iain Reeves, Gabriel Schembri, Nicola Mackie, Christine Bowman, Charles Lacey, Vanessa Apea, Michael Brady, Julie Fox, Stephen Taylor, Simone Antonucci, Saye Khoo, James F. Rooney, Anthony Nardone, Martin Fisher, Alan McOwan, Andrew Phillips, Anne M Johnson, Brian Gazzard, O N Gill - The Lancet 2015 cited by 1,893

  2. Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease

    Authors: Mark Bower, Tom Powles, Sarah Williams, Tom Newsom Davis, Mark Atkins, Silvia Montoto, Chloe Orkin, A. Webb, Martin Fisher, Mark Nelson, Brian Gazzard, Justin Stebbing, Peter Kelleher - Annals of Internal Medicine 2007 cited by 196

  3. Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease

    Authors: Mark Bower, Tom Newsom‐Davis, Kikkeri N. Naresh, Shairoz Merchant, Belinda Lee, Brian Gazzard, Justin Stebbing, Mark Nelson - Journal of Clinical Oncology 2011 cited by 179

  4. Early and nonreversible decrease of CD161++/MAIT cells in HIV infection

    Authors: Cormac Cosgrove, James E. Ussher, Andri Rauch, Kathleen Gärtner, Ayako Kurioka, Michael Hühn, Krista Adelmann, Yu-Hoi Kang, Joannah R. Fergusson, Peter Simmonds, Philip Goulder, Ted H. Hansen, Julie Fox, Huldrych F. Günthard, Nina Khanna, Fiona Powrie, Alan Steel, Brian Gazzard, Rodney E. Phillips, John Frater, Holm H. Uhlig, Paul Klenerman - Blood 2012 cited by 312

  5. Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)

    Authors: Ann Sullivan, Dorthe Raben, Joanne Reekie, Michael Rayment, Amanda Mocroft, Stefan Eßer, Agathe León, Josip Begovać, Kees Brinkman, Robert Zangerle, Anna Grzeszczuk, Anna Vassilenko, Vesna Hadžiosmanović, Maksym Krasnov, Anders Sönnerborg, Nathan Clumeck, José M. Gatell, Brian Gazzard, Antonella d’Arminio Monforte, Jürgen K. Rockstroh, Jens Lundgren - PLoS ONE 2013 cited by 212

  6. Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

    Authors: Thomas Powles, David Robinson, Justin Stebbing, Jonathan Shamash, Mark Nelson, Brian Gazzard, Sundhiya Mandelia, Henrik Møller, Mark Bower - Journal of Clinical Oncology 2008 cited by 356

  7. Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015

    Authors: Dorthe Raben, Ann Sullivan, Amanda Mocroft, Galyna A Kutsyna, Vesna Hadžiosmanović, Anna Vassilenko, Nikoloz Chkhartisvili, В. М. Мицура, Court Pedersen, Jane Anderson, Josip Begovać, Ulrik Bak Dragsted, Barbara Bertisch, Anna Grzeszczuk, Jane Minton, Valentina Coca Necsoi, Maria Kitchen, Faïza Ajana, Anton Sokhan, Laura Comi, Paymaneh Farazmand, Dragica Pešut, Stéphane De Wit, José María Gatell, Brian Gazzard, Antonella d’Arminio Monforte, Jürgen K. Rockstroh, Yazdan Yazdanpanah, Karen Champenois, Marie Louise Jakobsen, Jens Lundgren, on behalf of the HIDES Study Group - PLoS ONE 2019 cited by 67

  8. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment

    Authors: Ann Sullivan, John B. Saunders, Monica Desai, Andrea Cartier, Holly Mitchell, Sajjida Jaffer, Dana Ogaz, Chiara Chiavenna, André Charlett, Victor Diamente, Rainer Golombek, Kaveh Manavi, Cecilia Priestley, Laura Waters, Ana Milinkovic, Alan McOwan, Claudia Estcourt, Caroline Sabin, Alison Rodger, Deborah T. Gold, Brian Gazzard, Sheena McCormack, O Nöel Gill - The Lancet HIV 2023 cited by 52

  9. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

    Authors: Mark Nelson, Christine Katlama, Joan Montaner, David A. Cooper, Brian Gazzard, Bonaventura Clotet, Adriano Lazzarin, Knud Schewe, Joep M. A. Lange, Christina Wyatt, Sue Curtis, Shan-Shan Chen, Stephen A. Smith, Norbert Bischofberger, James F. Rooney - AIDS 2007 cited by 352

  10. Increasing burden of liver disease in patients with HIV infection

    Authors: Deepak Joshi, John O’Grady, Doug Dieterich, Brian Gazzard, Kosh Agarwal - The Lancet 2011 cited by 304

  11. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants

    Authors: Frank J. Palella, Martin Fisher, Pablo Tebas, Brian Gazzard, Peter Ruane, Jan van Lunzen, David Shamblaw, Jason Flamm, Ramin Ebrahimi, Danielle Porter, Kirsten White, Jason T. Hindman, Elizabeth Elbert, Shampa De-Oertel, Todd Fralich - AIDS 2013 cited by 118

  12. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Authors: Joel E. Gallant, Edwin DeJesus, José Ramón Arribas, Anton Pozniak, Brian Gazzard, Rafael Campo, Biao Lu, Damian J. McColl, Steven L. Chuck, Jeffrey Enejosa, John J. Toole, Andrew Cheng - New England Journal of Medicine 2006 cited by 886

  13. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome

    Authors: John Walsh, Sundhiya Mandalia, Brian Gazzard - AIDS 2002 cited by 450

  14. A Meta-analysis of Transient Elastography for the Detection of Hepatic Fibrosis

    Authors: Justin Stebbing, Lavanta Farouk, George Panos, Mike Anderson, Long R. Jiao, Sundhiya Mandalia, Mark Bower, Brian Gazzard, Mark Nelson - Journal of Clinical Gastroenterology 2010 cited by 213

  15. Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

    Authors: Frank van Leth, Prahpan Phanuphak, Erik S.G. Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J.P. Kastelein, Mauro Schechter, Robert L Murphy, Andrzej Horban, David B. Hall, Joep M. A. Lange, Peter Reiss - PLoS Medicine 2004 cited by 276

  16. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

    Authors: M I Filipe, F Potet, Wladimir V. Bogomoletz, Paul A. Dawson, Bettina Fabiani, P Chauveinc, A Fenzy, Brian Gazzard, D Goldfain, R Zeegen - Gut 1985 cited by 204

  17. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease

    Authors: Tom Powles, Justin Stebbing, A. Bazeos, Eleftheria Hatzimichael, Sundhiya Mandalia, Mark Nelson, Brian Gazzard, Mark Bower - Annals of Oncology 2009 cited by 168

  18. Protease inhibitors potentiate chemotherapy-induced neutropenia

    Authors: Mark Bower, Neil McCall-Peat, Natalie S. Ryan, Liz Davies, Anne Marie Young, Srirupa Gupta, Mark Nelson, Brian Gazzard, Justin Stebbing - Blood 2004 cited by 119

  19. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy

    Authors: Christopher M. Mela, Catherine Burton, Nesrina Imami, Mark Nelson, Alan Steel, Brian Gazzard, Frances Gotch, Martin R. Goodier - AIDS 2005 cited by 87

  20. The EuroSIDA study: 25 years of scientific achievements

    Authors: Kamilla Grønborg Laut, Ole Kirk, Jürgen K. Rockstroh, Andrew Phillips, Bruno Ledergerber, José M. Gatell, Brian Gazzard, Andrzéj Horban, Igor Karpov, Marcelo H. Losso, Antonella d’Arminio Monforte, C Pedersen, Matti Ristola, Peter Reiss, AU Scherrer, Stéphane De Wit, Inka Aho, Line Dahlerup Rasmussen, Veronica Svedhem, Gilles Wandeler, Christian Pradier, Nikoloz Chkhartishvili, Raimonda Matulionytė, Cristiana Oprea, Justyna Kowalska, Josip Begovać, JM Miró, Giovanni Guaraldi, Roger Paredes, Dorthe Raben, Daria Podlekareva, Lars Peters, Jens Lundgren, Amanda Mocroft - HIV Medicine 2019 cited by 34

  21. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

    Authors: Mark Sharkey, Ian Teo, Thomas Greenough, Н. П. Шарова, Katherine Luzuriaga, John L. Sullivan, R. Pat Bucy, Leondios G. Kostrikis, Ashley T. Haase, Claire Veryard, Raul Davaro, Sarah H. Cheeseman, Jennifer S. Daly, Carol Bova, Richard T. Ellison, B. J. Mady, Kwan Kew Lai, G Moyle, Mark Nelson, Brian Gazzard, Sunil Shaunak, Mario Stevenson - Nature Medicine 2000 cited by 432

  22. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

    Authors: Margaret May, Mark Gompels, Valérie Delpech, Kholoud Porter, Frank Post, Margaret Johnson, David Dunn, Adrian Palfreeman, Richard Gilson, Brian Gazzard, Teresa Hill, John Walsh, Martin Fisher, Chloe Orkin, Jonathan Ainsworth, L. Bansi, Andrew Phillips, Clifford Leen, Mark Nelson, Jane Anderson, Caroline Sabin - BMJ 2011 cited by 361

  23. Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma

    Authors: Mark Bower, Mark Nelson, Anne Marie Young, Christina Thirlwell, Tom Newsom‐Davis, Sundhiya Mandalia, T. Dhillon, Paul Holmes, Brian Gazzard, Justin Stebbing - Journal of Clinical Oncology 2005 cited by 269

  24. Epidemiology and Predictive Factors for Chemokine Receptor Use in HIV‐1 Infection

    Authors: Graeme Moyle, Adrian Wildfire, Sundhiya Mandalia, Howard Mayer, J. M. Goodrich, Jeannette M. Whitcomb, Brian Gazzard - The Journal of Infectious Diseases 2005 cited by 228